- #1
- 3,759
- 4,199
- TL;DR Summary
- Preliminary data from trials of two new treatments for Ebola suggest that they can cure ~90% of infected individuals.
This week, the US National Institutes of Health released an update on a trial in the Democratic Republic of the Congo comparing the effectiveness of two new antibody-based drugs (REGN-EB3 and mAb114) against existing treatments for Ebola (ZMapp and remdesivir). The trial was halted early because the data showed that the new drugs showed they were much more effective than the other treatments, so the NIH will now administer the new treatments to all patients in the study.
Formal analysis and publication of the trial results awaits completion of data collection, which is expected to finish in late Sep/early Oct.
Combined with experimental vaccines, these new treatments can hopefully help contain the current Ebola outbreak and future outbreaks, though quickly administering the drugs to infected individuals remains an issue (especially where there is violence and distrust of governments, as is the case with the currrent outbreak in the DRC).
https://www.nytimes.com/2019/08/12/health/ebola-outbreak-cure.htmlAmong patients who were brought into treatment centers with low viral loads — which suggested that they had been infected only days before — only 6 percent of those who got Regeneron drug died, and only 11 percent of those who got the Biotherapeutics drug died, Dr. Fauci said.
By contrast, 33 percent of those who received the antiviral drug made by Gilead died, as did 24 percent of those who got ZMapp, an older monoclonal antibody cocktail that was tested briefly during the Ebola outbreak in West Africa in 2014.
The death rate among untreated and unvaccinated patients in this outbreak is thought to be over 70 percent, said Dr. Michael J. Ryan, director of emergency response for the W.H.O.
Formal analysis and publication of the trial results awaits completion of data collection, which is expected to finish in late Sep/early Oct.
Combined with experimental vaccines, these new treatments can hopefully help contain the current Ebola outbreak and future outbreaks, though quickly administering the drugs to infected individuals remains an issue (especially where there is violence and distrust of governments, as is the case with the currrent outbreak in the DRC).